Explosive growth in renal artery interventional procedures; More cardiologists performing procedures

September 01, 2004

The annual number of Medicare beneficiaries who underwent renal artery interventional procedures to unblock arteries more than doubled between 1996 and 2000, with much of the growth attributed to more cardiologists beginning to do these procedures, according to a new study.

Historically, these procedures were done by interventional radiologists. These procedures are often done to treat hypertension, however, randomized clinical trials haven't shown that they actually do control a patient's blood pressure.

The study reviewed data from Medicare claims. In 1996 radiologists performed 4,700 renal artery interventional procedures (balloon angioplasty, stent or both), while cardiologists performed 2,380, said Timothy Murphy, MD, associate professor of radiology, Brown University Medical School, and lead author of the study. By 2000, cardiologists did 9,220 of these procedures (a 3.9-fold increase in annual volume) while radiologists increased the performance of this service to 7,660 (a 1.6-fold increase in annual volume). "It is important to note that cardiologists self-refer, and that could be one of the reasons why there is such a large increase in the number of procedures they are doing," Dr. Murphy said.

The greatest increase in the use of renal artery interventions occurred in the southeast (Alabama, Kentucky, Mississippi, North Carolina, South Carolina and Tennessee) with an increase from 22 per 100,000 Medicare beneficiaries in 1996 to 86 per 100,000 beneficiaries in 2000. The annual volume of renal artery interventions by cardiologists increased more than 15-fold in this region, Dr. Murphy said. "If this growth rate by cardiologists in the southeast region continues, at the end of 10 years, every man, woman and child in these states will have had a renal artery stent," he said.

The lowest rate of increase was in the northeast (Connecticut, Maine, Massachusetts, New Hampshire, New York, Rhode Island, Vermont): 18 per 100,000 beneficiaries in 1996 to 26 per 100,000 beneficiaries in 2000. The regional differences "prove there is no consensus on how these patients should be treated. Somebody is wrong. Patients are either being over or under treated," Dr. Murphy said.

"Blockages in the renal arteries is common, seen in 6-18% of patients undergoing coronary arteriography and in 16-40% of those patients undergoing aortography for aneurysms or peripheral vascular disease," Dr. Murphy said. The average hospital cost for a renal artery stent is about $10,000, Dr. Murphy said. "If you look at these numbers, and you look at the mind-boggling growth in renal artery interventional procedures, you could be talking about several hundred million dollars, even up to more than a billion dollars annually to treat these patients," he said.

A multi-center clinical trial is scheduled to begin the end of this year to determine the best role for renal artery angioplasty. In the past, clinical trials have looked at its effect on hypertension, and have found little benefit, Dr. Murphy said. This trial will examine its affect on stroke, heart attack, heart failure and worsening renal function, he said. This study should help resolve the confusion regarding the need for renal artery stenting, he added.
-end-
The study appears in the September issue of the American Journal of Roentgenology.

American College of Radiology

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.